Keywords: biocryst, takes, off, positive, phase, ii, influenza
BioCryst takes off on positive Phase II influenza drug data
Article | 27 August 1999
BioCryst Pharmaceuticals has revealed promising data from a Phase IItrial of its neuraminidase inhibitor, RWJ 270201, in healthy adults infected with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
